Bioprinted cardiac tissue to be used for toxicology screening for early drug candidates

Written by Georgi Makin

Bayer (Leverkusen, Germany) and Ramot at Tel Aviv University (Israel) have announced a collaboration for toxicology screening for early drug candidates on bioprinted cardiac tissue. Bayer (Leverkusen, Germany) and Ramot at Tel Aviv University (Israel) – Tel Aviv University’s technology transfer company – have announced a collaboration for the development and validation of a platform for toxicology screening on bioprinted human cardiac tissues. Bayer and the Laboratory for Tissue Engineering and Regenerative Medicine at Tel Aviv University plan to screen for toxicity and efficacy by testing pharmaceuticals on 3D-printed in vitro whole human heart models. The team at the Laboratory...

To view the full article, please register now for access

It's completely free